A NIR fluorescent probe for fatty acid amide hydrolase bioimaging and its application in development of inhibitors

被引:9
|
作者
Tian, Manman [1 ]
Tian, Zhenhao [3 ]
Yao, Dahong [4 ]
Ning, Jing [1 ]
Deng, Sa [1 ]
Feng, Lei [1 ,5 ]
Huo, Xiaokui [1 ]
Tian, Xiangge [1 ]
Zhang, Baojing [1 ]
Wang, Chao [1 ]
Yu, Zhenlong [1 ]
Ma, Xiaochi [1 ,2 ]
机构
[1] Dalian Med Univ, Affiliated Hosp 2, Coll Pharm, Dalian, Peoples R China
[2] Xuzhou Med Univ, Jiangsu Key Lab New Drug Res & Clin Pharm, Xuzhou 221004, Jiangsu, Peoples R China
[3] Northwestern Polytech Univ, Sch Life Sci, Xian 710072, Peoples R China
[4] Shenzhen Technol Univ, Sch Pharmaceut Sci, Shenzhen 518118, Peoples R China
[5] Henan Normal Univ, Sch Chem & Chem Engn, Xinxiang 453007, Henan, Peoples R China
基金
中国国家自然科学基金;
关键词
CLINICAL-TRIAL; FAAH; ENZYME; PAIN;
D O I
10.1039/d1tb01054a
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Fatty acid amide hydrolase (FAAH) is primarily responsible for the inactivation of fatty acid ethanolamide (FAE) and is involved in a variety of biological functions related to diseases of the nervous system. Herein, we developed a highly selective and sensitive FAAH-activated near-infrared fluorescent probe named DAND and achieved the real-time detection and imaging of FAAH activity in complex biosystems. Moreover, a visual high-throughput screening method was established using DAND, piperine was identified as a novel inhibitor of FAAH. Based on the interaction of piperine with FAAH, a more potent FAAH inhibitor (11f) was designed and synthesized which possessed an IC50 value of 0.65 mu M. Furthermore, 11f could attenuate the liposaccharide (LPS)-induced activation of BV2 cells, exhibiting an excellent anti-inflammatory activity. These results indicated that DAND could be used as a promising molecular tool for exploring FAAH activity and for rapidly screening potential FAAH inhibitors. In addition, piperine and its derivatives could serve as potential candidate drugs for the treatment of neurodegenerative diseases in the future.
引用
收藏
页码:6460 / 6465
页数:6
相关论文
共 50 条
  • [21] A Systems Pharmacology Perspective on the Clinical Development of Fatty Acid Amide Hydrolase Inhibitors for Pain
    Benson, N.
    Metelkin, E.
    Demin, O.
    Li, G. L.
    Nichols, D.
    van der Graaf, P. H.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (01):
  • [22] Identification of Endogenous Inhibitors of Fatty Acid Amide Hydrolase in the Liver
    Liu, Jie
    Cinar, Resat
    Xiong, Keming
    Ntambi, James M.
    Kunos, George
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [23] Heterocyclic sulfoxide and sulfone inhibitors of fatty acid amide hydrolase
    Du, W
    Hardouin, C
    Cheng, H
    Hwang, I
    Boger, DL
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (01) : 103 - 106
  • [24] Benzylamides and piperazinoarylamides of ibuprofen as fatty acid amide hydrolase inhibitors
    Deplano, Alessandro
    Cipriano, Mariateresa
    Moraca, Federica
    Novellino, Ettore
    Catalanotti, Bruno
    Fowler, Christopher J.
    Onnis, Valentina
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2019, 34 (01) : 562 - 576
  • [25] Design, synthesis, and evaluation of fatty acid amide hydrolase inhibitors
    Boger, Dale L.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [26] Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase
    Bisogno, T
    Melck, D
    De Petrocellis, L
    Bobrov, MY
    Gretskaya, NM
    Bezuglov, VV
    Sitachitta, N
    Gerwick, WH
    Di Marzo, V
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 248 (03) : 515 - 522
  • [27] Next Stop for Fatty Acid Amide Hydrolase Inhibitors, the Clinic?
    Piomelli, Daniele
    BIOLOGICAL PSYCHIATRY, 2020, 87 (06) : 485 - 486
  • [28] Latest advances in the discovery of fatty acid amide hydrolase inhibitors
    Bisogno, Tiziana
    Maccarrone, Mauro
    EXPERT OPINION ON DRUG DISCOVERY, 2013, 8 (05) : 509 - 522
  • [29] Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: A probe of structural and conformational features contributing to inhibition
    Boger, DL
    Sato, H
    Lerner, AE
    Austin, BJ
    Patterson, JE
    Patricelli, MP
    Cravatt, BF
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (02) : 265 - 270
  • [30] Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors
    Kodani, Sean D.
    Wan, Debin
    Wagner, Karen M.
    Hwang, Sung Hee
    Morisseau, Christophe
    Hammock, Bruce D.
    ACS OMEGA, 2018, 3 (10): : 14076 - 14086